Direct Plan · Growth · Balanced Advantage · Scheme code 149406
NAV₹16.6598as on 13 Nov 2026
Fund houseMahindra Manulife Mutual Fund
CategoryBalanced Advantage
Plan & optionDirect · Growth
History4.9 years
Returns (%)
1M
3M
6M
1Y
3Y
5Y
7Y
10Y
Launch
This scheme
6.72
2.08
7.79
5.26
12.13
—
—
—
11.05
NIFTY 100 TRI benchmark
-6.50
-6.49
1.68
-6.82
7.47
6.95
11.99
11.58
13.28
Balanced Advantage category median
—
—
—
3.73
10.36
9.31
—
10.70
—
Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
10.5%
0.54
0.79
0.67
2.64%
-9.8%
89.33
NIFTY 100 TRI benchmark
14.8%
0.07
0.09
—
—
-37.9%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
36 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
948
-2.3%
8.5%
35.1%
1%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
How it behaves against its benchmark
Up capture
Down capture
Correlation
Tracking error
Information ratio
Treynor
80%
56%
0.95
6.0%
0.41
6.66
Up capture is how much of the benchmark's gain this scheme kept in the months the
benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it
on the up side is the combination every fund is trying for and few reach.
Measured over the 36 months this scheme and
NIFTY 100 TRI share.
Mahindra Manulife Balanced Advantage Fund
Direct Plan · Growth
Allocation
By asset
Equity
68.62%
Debt
21.19%
REITs / InvITs
6.76%
Cash & Equivalents
5.18%
By market cap
Large Cap
43.92%
Mid Cap
18.21%
Small Cap
11.57%
Unclassified
22.87%
Concentration
Number of stocks
79
Top 5 stocks
18.84%
Top 10 stocks
30.67%
Top 20 stocks
47.14%
Lines in the filing
83
Largest holding
4.74%
Largest sector
Banks 16.40%
Effective stocks
56.9
Sectors held
35
Cash
0.00%
Effective stocks is what the concentration works out to: a fund holding
79 names but most of its money in a few
behaves like a fund of 57. Cash includes repo and TREPS, which
every fund parks money in overnight.
Sector split
Banks
16.40%
SOVEREIGN
9.25%
Pharmaceuticals & Biotechnology
7.72%
Realty
6.41%
CRISIL AA+
5.71%
CRISIL AAA
5.36%
Cash & Equivalents
5.18%
Retailing
4.31%
IT - Software
4.08%
Telecom - Services
3.40%
Finance
3.06%
Automobiles
3.00%
Capital Markets
2.41%
Petroleum Products
2.34%
Aerospace & Defense
2.03%
Healthcare Services
1.80%
Ferrous Metals
1.70%
Industrial Products
1.66%
Transport Services
1.60%
ICRA AAA
1.41%
Mahindra Manulife Balanced Advantage Fund
Direct Plan · Growth · holdings as on 31 Oct 2026
Top 30 holdings
#
Company
Sector
Shares held
Value ₹ cr
% of fund
1
Brookfield India Real Estate Trust
Realty
1,311,396
41
4.74%
2
ICICI Bank Limited
Banks
257,500
36
4.14%
3
7.24% Government of India 2055
SOVEREIGN
3,500,000
33
3.74%
4
7.71% Government of India 2066
SOVEREIGN
3,000,000
29
3.37%
5
8.52% Muthoot Finance Limited 2028
CRISIL AA+
2,500,000
25
2.85%
6
Bharti Airtel Limited
Telecom - Services
118,000
23
2.68%
7
Eternal Limited
Retailing
605,000
21
2.39%
8
Reliance Industries Limited
Petroleum Products
175,000
20
2.34%
9
HDFC Bank Limited
Banks
291,201
20
2.32%
10
Axis Bank Limited
Banks
150,000
18
2.10%
11
Laurus Labs Limited
Pharmaceuticals & Biotechnology
75,761
18
2.09%
12
Tech Mahindra Limited
IT - Software
94,000
17
1.93%
13
Apollo Hospitals Enterprise Limited
Healthcare Services
18,500
16
1.80%
14
Net Receivables / (Payables)
Unclassified
—
15
1.75%
15
Jindal Steel Limited
Ferrous Metals
139,812
15
1.70%
16
IndusInd Bank Limited
Banks
176,000
15
1.69%
17
Net Receivables / (Payables)
Unclassified
—
15
1.69%
18
Triparty Repo
Unclassified
—
15
1.68%
19
The Federal Bank Limited
Banks
420,000
14
1.64%
20
State Bank of India
Banks
131,500
13
1.45%
21
Larsen & Toubro Limited
Construction
31,400
12
1.40%
22
Bajaj Finance Ltd
Finance
129,549
12
1.40%
23
Senores Pharmaceuticals Limited
Pharmaceuticals & Biotechnology
105,000
12
1.37%
24
Titan Company Limited
Consumer Durables
26,500
12
1.35%
25
Aditya Vision Ltd
Retailing
206,658
11
1.30%
26
Mahindra & Mahindra Limited
Automobiles
39,600
11
1.29%
27
Glenmark Pharmaceuticals Limited
Pharmaceuticals & Biotechnology
48,065
11
1.27%
28
Divi's Laboratories Limited
Pharmaceuticals & Biotechnology
11,300
11
1.27%
29
Bank of Maharashtra
Banks
1,337,000
11
1.25%
30
Bharat Heavy Electricals Limited
Electrical Equipment
278,000
11
1.24%
Mahindra Manulife Balanced Advantage Fund
Direct Plan · Growth · where the money sits
What the manager did last month
Between the filings of 30 Sep 2026 and 31 Oct 2026.
A position grows because the manager bought or because the price rose; only the share count separates them.
Bought
Sold
New positions
Sold out of
Price move of holdings
₹29 cr
₹5 cr
4
2
+0.58%
Stock
Shares traded
Shares
Price
Value ₹ cr
New position
Sagility Limited
900,000
entered
—
3.8
One 97 Communications Limited
20,000
entered
—
3.3
HBL Engineering Limited
40,500
entered
—
3.2
Embassy Office Parks REIT
71,764
entered
—
3.0
Added to
Brookfield India Real Estate Trust
745,000
+131.5%
-6.4%
23.5
Tech Mahindra Limited
10,000
+11.9%
+17.5%
1.8
Senores Pharmaceuticals Limited
15,000
+16.7%
-18.2%
1.7
HDFC Asset Management Company Limited
5,600
+28.0%
+1.3%
1.3
Reliance Industries Limited
10,000
+6.1%
-1.9%
1.2
Trimmed
IndusInd Bank Limited
30,000
-14.6%
-7.0%
2.5
Aditya Birla Sun Life AMC Limited
25,401
-31.8%
-19.1%
2.1
Sold out of
Fortis Healthcare Limited
130,000
exited
—
10.0
Arvind Fashions Limited
49,822
exited
—
1.9
Not equity
Previous filing
This filing
Change
Cash, repo and TREPS
₹0 cr
₹0 cr
+₹0 cr
Debt: bills, CDs and commercial paper
₹200 cr
₹184 cr
−₹16 cr
The list above is stocks and fund units. Treasury bills, repo and money-market
lines roll over every month by design — they are not decisions, so they are totalled here rather
than listed as activity.
Not investment advice. MF Analyser is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 14 Nov 2026.